BMD: A Continuum of Risk WHO Bone Density Criteria

Similar documents
Disclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis

Skeletal Manifestations

Understanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now?

IEHP UM Subcommittee Approved Authorization Guidelines DEXA Scan

Practical Management Of Osteoporosis

Bone Densitometry Pathway

Sarena Ravi MD, MPH Endocrinologist. Franciscan Physicians Network Division of Endocrinology Chicago, IL

Case Finding and Risk Assessment for Osteoporosis

Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017

Current and Emerging Strategies for Osteoporosis

Using the FRAX Tool. Osteoporosis Definition

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

Beyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO

Osteoporosis/Fracture Prevention

Osteoporosis. Treatment of a Silently Developing Disease

Management of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.

Osteoporosis Management

Metabolic Bone Disease and the Gastroenterologist

Aromatase Inhibitors & Osteoporosis

Major Recommendations Recommendations apply to postmenopausal women and men age 50 and older.

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

Fractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases

Normal Bone Health and Bone Disease. Mr Ryan Trickett Consultant Hand and Wrist Surgeon 6 th February 2017

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

SECONDARY CAUSES OF OSTEOPOROSIS

Bone Health Update Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh

Clinical Practice. Presented by: Internist, Endocrinologist

Secondary Osteoporosis

Bone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017

DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi

Disclosures Fractures:

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.

Osteoporosis challenges

Osteoporosis in Men Eric Orwoll Oregon Health & Science University

[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.

Use of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD

3. Has bone specific alkaline phosphatase level increased OR does the member have symptoms related to active Paget s?

Management of Osteoporosis Clinical Practice Guideline September 2013

Hyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012

ASJ. How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility? Asian Spine Journal. Introduction

OSTEOPOROSIS: AN OPPORTUNITY OR OBLIGATION

Screening Guidelines: Women

Comprehensive Review of Osteoporosis. Alyse Chandler, PharmD, BCPS, CDE March 11, 2018

LOVE YOUR BONES Protect your future

International Journal of Health Sciences and Research ISSN:

Clinician s Guide to Prevention and Treatment of Osteoporosis

Bone Health in Women: Getting Strong and Staying Strong Family Medicine Refresher Course

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

Osteoporosis - Pathophysiology and diagnosis. Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark

Study of secondary causes of male osteoporosis

Forteo (teriparatide) Prior Authorization Program Summary

ENTITLEMENT ELIGIBILITY GUIDELINES OSTEOPOROSIS

AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care

Osteoporosis Screening and Treatment in Type 2 Diabetes

NIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11.

Men and Osteoporosis So you think that it can t happen to you

MEDICAL POLICY MEDICARE ADVANTAGE ONLY (See Product Variations)

Awareness, Diagnosis, and Management of Osteoporosis in Adults with Developmental Disabilities

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

Page 1. New Developments in Osteoporosis. What s New in Osteoporosis

Original Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT

Bone (Mineral) Density Studies

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview

An audit of osteoporotic patients in an Australian general practice

COURSE OUTLINE - Module I

Osteoporosis, Osteomalasia & rickets. Bone disorders

Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck

Vitamin D Deficiency. Micol Rothman, MD Assistant Professor of Medicine Clinical Director Metabolic Bone Program University of CO-Denver

FRAX, NICE and NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield

Learning Objectives. ! Students will become familiar with the 3 treatment solutions for osteoporosis. ! Students should be able to define osteoporosis

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

OSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE. Lydia Au Geriatrics Ng Teng Fong Hospital

Vitamin D Hormone Du Jour

NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT

Dr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk

Osteoporosis in Men. CME Away India & Sri Lanka March 23 - April 7, 2018

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING

Diagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.

Defining Bone Health and Fracture Risk in West Virginia: The World Health Organization FRAX Assessment Tool

Chau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences

Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Management of Osteoporosis

Therapeutic Updates in the Prevention and Treatment of Osteoporosis

10/26/2017. Aging Population = more osteoporosis

52% 34% 5. Both 1) and 3) Start calcium... Both 1) and 3) Start alendron... Start raloxife... Page 1

Osteoporosis: Who, What, When, Why, and How

Pharmacy Management Drug Policy

Everyone knows 1/15/2018. Does Osteopenia Warrant Treatment? Osteoporosis Prevention: Is it Ever Warranted?

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

Osteoporosis and osteoporotic fracture : A silent enemy of elderly people Islam MS

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008

Transcription:

Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco POOR BONE QUALITY FRACTURES LOW BONE DENSITY FALLS Modified from Riggs BL and Melton LJ III. Osteoporosis: Etiology, Diagnosis, and Management. New York: Raven Press; 1988. BMD: A Continuum of Risk WHO Bone Density Criteria Relative Risk of Fracture 35 30 25 20 15 10 5 0 Osteoporosis Low Bone Mass Normal -5-4 -3-2 -1 0 1 2 BMD T-Score Diagnostic criteria* T is above or equal to -1 T is between -1 and -2.5 T is -2.5 or lower T is -2.5 or lower + fragility fracture Classification Normal Osteopenia (low bone mass) Osteoporosis Severe, established osteoporosis * Measured in "T-scores;" the T-score indicates the number of standard deviations above or below the average peak bone mass in young adults Meunier PJ, et al. Clin Ther. 1999;21:1025-1044. NOF Clinician s Guide to Prevention and Treatment of Osteoporosis 2008. www.nof.org.

Treatment Threshold Concept Risk Factors for Fracture: Beyond Age + T-score 10-Year Fracture Probability (%) 40 30 20 AGE 80 70 60 Current treatment threshold based on T-score Treatment threshold concept based on WHO Absolute Fracture Risk Risk Factor RR (95% CI) Prior Fracture 1.62 (1.30-2.01) Parental History of Hip Fracture 2.28 (1.48-3.51) Current Smoking 1.60 (1.27-2.02) 10 50 Systemic Corticosteroids 2.25 (1.60-3.15) Alcohol Intake 3 Units Daily 1.70 (1.20-2.42) 0-3 -2.5-2 -1.5-1 -0.5 0 0.5 1 Rheumatoid Arthritis 1.74 (0.94-3.20) BMD T-score Adapted from JA Kanis et al, Osteoporos Int. 2001;12:989-995 Kanis J, et al. Osteoporos Int. 2005;16:581 Patients With Prior Fracture Have a High Risk of Future Fragility Fractures Calculating Absolute Fracture Risk: FRAX http://www.shef.ac.uk/frax/tool.jsp Prior fracture Relative risk of future fracture Wrist Vertebra Hip Wrist 3.3 1.7 1.9 Vertebra 1.4 4.4 2.3 Hip NA 2.5 2.3 Klotzbuecher CM, et al. J Bone Miner Res. 2000;15:721-39

50-Year-Old Woman With T-score -2.0: Effect Of Additional Risk Factors 40 Risk of Major Fractures Risk of Hip Fracture FRAX Model: Caveats h It is not clear what margin of error is present in the fracture risk estimates 10-Year Fracture Risk (%) 30 20 10 0 7 7.6 13 1.2 2.2 2.6 Smoking Smoking Parental Hip Fx 24 4.8 Smoking Parental Hip Fx Wrist Fx h The model does not fully account for the fracture risk associated with falling h It is not obvious that all risk factors carry equal weight in predicting the response to pharmacologic treatment 2008 NOF Guidelines: Treatment Initiation Post-menopausal Women And Men 50 Hip or Vertebral Fractures or T-score -2.5 (Spine, FN or Total Hip) Assess Risk Factors and Measure BMD if Patient Has Risk Factors Other Fractures after Age 50 (Excluding Fingers, Toes and Face) T-score between -1.0 and -2.5 10-year Probability of Hip Fracture >3% or Probability of All Major Fractures >20% Secondary Causes with High Fracture Risk* *such as glucocorticoid use or total immobilization Differential Diagnosis Of Low BMD h Primary osteoporosis (postmenopausal or age-related) h Secondary osteoporosis (caused, wholly or in part, by other diseases or medications) 0Secondary causes are not rare h Idiopathic osteoporosis (disease characterized by low bone density and fractures in young adults without known cause) h Other bone diseases 0Osteogenesis imperfecta 0Osteomalacia 0Renal osteodystrophy http://www.nof.org

Some Causes Of Secondary Osteoporosis In Adults Most Common Causes Of Secondary Osteoporosis Endocrine/Metabolic Nutritional Conditions Drugs Collagen Disorders Other Hypogonadism Hyperadrenocorticism Thyrotoxicosis Anorexia nervosa Hyperprolactinemia Porphyria Hypophosphatasia, in adults Diabetes mellitus, Type 1 Hyperparathyroidism Acromegaly Malabsorption syndromes Malnutrition Chronic cholestatic liver disease Gastric operations Vitamin D deficiency Calcium deficiency Alcoholism Hypercalciuria Adapted from AACE Guidelines on Osteoporosis Glucocorticoids Excess thyroid hormone Heparin GnRH agonists Phenytoin Phenobarbital Depo-Provera Aromatase inhibitors Osteogenesis imperfecta Homocystinuria Ehlers - Danlos syndrome Marfan syndrome Rheumatoid arthritis Myeloma and some cancers Immobilization Renal tubular acidosis COPD Organ transplantation Mastocytosis Thalassemia Diseases Conditions Drugs Hypogonadism Malabsorption COPD Rheumatoid arthritis Myeloma Vitamin D deficiency Hypercalciuria Some unsuspected Steroid therapy Antiepileptics GnRH agonists Depo-Provera Aromatase inhibitors Excess thyroxine How Often Do Healthy Women With Osteoporosis Have Unsuspected Disorders? Study population: 664 consecutive postmenopausal women with a T-score of -2.5 or below i 54% excluded for a known secondary cause i 173 females (ages 46-87) without known secondary osteoporosis or prior lab abnormalities underwent lab evaluation CBC, chemistry, 24-hour urine calcium, PTH, 25-OH vitamin D, most also had TSH, SPEP 44% of patients were found to have a secondary cause Osteoporotic Women With New Diagnoses Vitamin D deficiency (25-OH D <20 ng/ml) 20% Hypercalciuria 10% Malabsorption 7% iceliac disease (3) Hyperparathyroidism 3% iprimary (1) isecondary (5) Over-replacement with T4 (4) 2% Cushing s disease (1) <1% Other 1% Data reanalyzed from Tannenbaum C, et al. J Clin Endocrinol Metab. 2002;87(10):4431 using current definition of vitamin D deficiency (personal communication: Luckey MM) Data reanalyzed from Tannenbaum C, et al. J Clin Endocrinol Metab. 2002;87(10):4431 using current definition of vitamin D deficiency (personal communication: Luckey MM)

Prevalence of Occult Secondary Osteoporosis h Prevalence in studies that assessed urinary calcium and vitamin D: 0Women and men, varying ages: 1-4 37% 63% 0Post-hip fracture patients: 5 60% 80% 0Bone loss on pharmacologic therapy: 6,7 50% No large, population-based studies; studies from referral centers vary by criteria for inclusion, extent of testing, and definition of vitamin D deficiency 1.Deutschman HA et al. J Intern Med. 2002;252:389 2.Haden ST et al. Calcif Tissue Int. 1999;64:275 3.Ryan CS et al. Presented at: 27th ASBMR Annual Meeting; September 2005; Nashville, TN. Abstract SA380 4.Gabaroi DC et al. Menopause. 2010;17:135 5.Edwards BJ et al. Osteoporos Int. 2008;19:991 6.Lewiecki EM, Rudolph LA. J Bone Miner Res. 2002;17(Suppl 1):S367 7.Geller JL et al. Endocr Pract. 2008;14:293 Identifying the Patient with an Occult Disorder h All patients deserve at least a limited laboratory evaluation prior to treatment h No clinical parameter (even age or disease severity) identifies those most likely to have an occult disorder 1 h The available data do not suggest that occult disease is more likely in patients with low Z-scores (i.e., in those whose density is lower than expected for age) 1,2 h Persistent additional testing if there is a statistically significant BMD decrease on therapy 1. Tannenbaum C et al. J Clin Endocrinol Metab 2002;87:4431. 2. Gabaroi DC et al. Menopause. 2010;17:135. 3. NOF. Clinician s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: NOF; 2008. 4. DHHS. Report on Both Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US DHHS; 2004. Evaluation Of The Patient With Osteoporosis icareful history and examination ilaboratory testing Chemistry CBC 24 hour urine calcium (and creatinine) 25-OH vitamin D Thyroid function tests (TFTs) if symptoms warrant or the patient is on thyroid replacement therapy Identified 92% of new diagnoses at modest cost CBC Laboratory test Serum chemistry 0Albumin 0Globulin 0Alkaline phosphatase 0Calcium (high or low) 0Phosphate 0BUN, creatinine 25-OH vitamin D 24-hour urine calcium (and creatinine) Looking for myeloma; malabsorption of iron, B12, folate malabsorption; malnutrition myeloma malignancy, cirrhosis, vitamin D deficiency hyperparathyroidism, malabsorption malnutrition, osteomalacia renal disease vitamin D deficiency hypercalciuria, malabsorption Other tests as indicated by symptoms or results of above tests: 0 PTH if urine or serum calcium abnormally high or low 0 SPEP if CBC abnormal 0 Test for celiac disease if low 24-hour urine calcium or anemia

Importance of 24-hour Urine Calcium i Effectively identifies both hypercalciuria and malabsorption when results fall outside normal values (60-300 mg/day) with a calcium intake around 1000 mg daily Both disorders associated with higher rates of bone loss Calcium deficiency associated with diminished or absent BMD response to therapy Each condition requires a specific intervention for optimal patient management i Spot urine calcium does not detect malabsorption i 38% of new diagnoses would have been missed without 24 hour urine calcium results Evaluate for other causes of bone loss, especially those that are serious or correctable Low T-score Treatment Heaney RP, et al. Osteoporos Int 1999;9:13-18 Nieves JW 1998 Am J Nutr 67:182 Ciacci C, et al. Am J Gastroenterol. 1995;90:1480-4 Tannenbaum C, et al. J Clin Endocrinol Metab. 2002;87:4431-7